Streetbeat News

LGVN

Longeveron Inc.

https://www.longeveron.com

Industry

Biotechnology

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.

Open

1.68

Mkt cap

25M

Volume

73K

High

1.70

P/E Ratio

-0.65

52-wk high

6.40

Low

1.62

Div yield

N/A

52-wk low

0.77

Longeveron has filed a prospectus for the resale or other disposition of 3,563,764 shares by selling stockholders.

Portfolio Pulse from Bill Haddad

June 28, 2024 | 8:26 pm

Longeveron's (NYSE:LGVN) short interest has risen by 18.1%, with 55,000 shares sold short, representing 1.24% of its float. This increase in short interest could indicate bearish sentiment among investors. However, Longeveron's short interest is still below the peer group average of 2.16%.

Portfolio Pulse from Benzinga Insights

June 19, 2024 | 8:15 pm

The article highlights the pre-market movements of several health care stocks on Wednesday. Notable gainers include Sonoma Pharmaceuticals, Mustang Bio, Geovax Labs, Silk Road Medical, Onconetix, and Qualigen Therapeutics. Significant losers include DermTech, Biolase, Zentalis Pharma, Anitra, Virpax Pharmaceuticals, and Longeveron.

Portfolio Pulse from Benzinga Insights

June 19, 2024 | 12:06 pm

Longeveron shares are trading lower after the company announced agreements for the exercise of warrants for $4.4 million in gross proceeds.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 12:47 pm

Longeveron has entered into agreements for the exercise of warrants to purchase 1.7 million shares at $2.35 each, expected to raise $4.4 million. Additionally, the company has issued new warrants for 3.4 million shares at $2.50 each with a 24-month term.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 12:40 pm

AMMO, Inc. (NASDAQ:POWW) shares fell over 19% despite reporting a profit and higher-than-expected sales for the fourth quarter. Other notable stock movements include significant gains for Kaival Brands Innovations Group, Inc. (NASDAQ:KAVL) and SRIVARU Holding Limited (NASDAQ:SVMH), and declines for QXO, Inc. (NASDAQ:QXO) and Nexalin Technology, Inc. (NASDAQ:NXL).

Portfolio Pulse from Avi Kapoor

June 14, 2024 | 6:13 pm

The article highlights significant intraday movements in health care stocks on Friday. Cyclerion Therapeutics, CNS Pharma, Longeveron, iSpecimen, Scinai Immunotherapeutics, and Disc Medicine saw notable gains, while Nexalin Technology, Kyverna Therapeutics, Gain Therapeutics, IN8bio, Nanoviricides, and Rezolute experienced significant declines.

Portfolio Pulse from Benzinga Insights

June 14, 2024 | 4:31 pm

The article highlights the pre-market movements of various health care stocks on Friday. Notable gainers include Ainos (AIMD), Longeveron (LGVN), Bio-Path Holdings (BPTH), Moleculin Biotech (MBRX), Tonix Pharmaceuticals (TNXP), and Molecular Partners (MOLN). Significant losers include Opthea (OPT), Gain Therapeutics (GANX), Alzamend Neuro (ALZN), JanOne (JAN), Rezolute (RZLT), and Aethlon Medical (AEMD).

Portfolio Pulse from Benzinga Insights

June 14, 2024 | 12:06 pm

Signet Jewelers Limited (NYSE:SIG) shares fell over 12% due to mixed first-quarter earnings, including a significant drop in same-store sales. The company reported a 9.5% year-on-year sales decline, missing analyst estimates, but beat EPS expectations. Other stocks mentioned include BioRestorative Therapies, Zapp Electric Vehicles, Sharps Technology, and Broadcom, among others, with various gains and losses based on recent announcements and earnings reports.

Portfolio Pulse from Avi Kapoor

June 13, 2024 | 6:07 pm

Longeveron Inc. (NASDAQ: LGVN) shares have surged over 200% this week, driven by a positive report from Zacks Small Cap Research, a new contract for its manufacturing facility, and progress in its Phase 2b clinical trial for Lomecel-B. Despite the recent gains, the stock has decreased by 89.55% over the past year.

Portfolio Pulse from Erica Kollmann

June 13, 2024 | 5:13 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.